Immunomodulators in Vitiligo Management

Igor Korobko
VR Foundation, New York, USA

*Corresponding author: Igor Korobko, VR Foundation, New York, USA, E-mail: i.korobko@vrfoundation.org

Vitiligo is currently considered as a predominantly autoimmune disorder thus interventions with immunomodulating capacity provide a rational solution to halt vitiligo progression. Indeed, conventional treatments capable to stop progression of vitiligo, narrow-band ultraviolet B and systemic steroids, both are known to have immunosuppressive activity. While a number of experimental treatments were tested for their capacity to cope with vitiligo spreading, their widespread use is limited owing to frequent side effects or inconvenient and lengthy course of treatment, besides the efficiency of available options is not absolute. Therefore there is a need for new safe and convenient options to fight vitiligo progression, with immunomodulating compounds, owing to their frequently good safety profile and autoimmune nature of vitiligo, being attractive candidates. Here, available options to stop vitiligo progression are overviewed, with the most recent developments in the field, namely the use of non-steroid immunomodulators, being discussed in details.